# Sources — Emily Dickinson

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 3, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Emily Dickinson Museum. “Emily Dickinson: Her Childhood and Youth (1830-1855).” Supports her birth “on December 10, 1830, in the family Homestead on Main Street in Amherst, Massachusetts.” https://www.emilydickinsonmuseum.org/emily-dickinson/biography/emily-dickinson-her-childhood-and-youth-1830-1855/
2. Emily Dickinson Museum. “Emily Dickinson's Health.” Citing her letters, supports her month-long removal from Mount Holyoke Female Seminary in the late winter of 1848 for lung congestion and a cough; the consumptive symptoms of 1851 and the glycerine prescription she took for two years; the eye affliction that by her own account began in the fall of 1863 (L290), her consultation with the Boston ophthalmologist Henry Willard Williams in February 1864, her stays in Cambridgeport from April to December 1864 and from April to October 1865, after which she was apparently cured; the treatment of confinement in dim light, no reading, and writing only in pencil, and her phrase “eight months of Siberia”; iritis as the most likely explanation; her withdrawal from normal social situations from her mid-twenties; and the disagreement among scholars whether that withdrawal was an artistic choice or had a medical origin, “such as an anxiety condition.” https://www.emilydickinsonmuseum.org/emily-dickinson/biography/special-topics/emily-dickinsons-health/
3. Emily Dickinson Museum. “Emily Dickinson: The Later Years (1865-1886).” Supports that she “rarely ventured beyond the family Homestead,” that she became ill after a death in her family in the autumn of 1883, and that “she remained in poor health until she died at age 55 on May 15, 1886.” https://www.emilydickinsonmuseum.org/emily-dickinson/biography/emily-dickinson-the-later-years-1865-1886/
4. Emily Dickinson Museum. “Emily Dickinson and Death.” Citing her letters and Jay Leyda's *The Years and Hours of Emily Dickinson*, supports the two and a half years of ill health before her death, the “nervous prostration” that followed a death in her family in October 1883, two later “blackouts,” confinement to bed for the seven months before her death, the severe headache and nausea mentioned in her letters, her deathbed coma with raspy, difficult breathing, her physician's difficulty in examining her because she would not admit him to her bedside to take a pulse, and “Bright's Disease” as the cause entered on her death certificate, “at the time a general diagnosis that included hypertensive symptoms, as well as symptoms for nephritis.” It also states that researchers have concluded she died of heart failure induced by severe hypertension and that no documentary evidence notes the yellow pallor and odor associated with nephritis. https://www.emilydickinsonmuseum.org/emily-dickinson/biography/special-topics/emily-dickinson-and-death/
5. Blanchard DL. “Emily Dickinson's ophthalmic consultation with Henry Willard Williams, MD.” *Arch Ophthalmol* 2012;130(12):1591–1595. PMID 23229703. The abstract states that no records of the diagnosis survive; that photophobia, aching eyes, and a restriction in her ability to work up close were her main symptoms; that iritis, exotropia, or psychiatric problems are the diagnoses most often offered; and it adds hysterical hyperaesthesia of the retina as a further possibility. Only the abstract was read. https://pubmed.ncbi.nlm.nih.gov/23229703/
6. Hirschhorn N, Longsworth P. “Was it epilepsy?: misdiagnosing Emily Dickinson (1830-1886).” *Perspect Biol Med* 2013;56(3):371–386. PMID 24375119. The abstract refutes a proposed diagnosis of epilepsy on scientific, clinical, and biographical grounds. Only the abstract was read. https://pubmed.ncbi.nlm.nih.gov/24375119/
7. HISTMED Master Roster v3. Internal project source. Its clinical claims were provisional and were not treated as independent corroboration.

## Clinical guidance

1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int* 2024;105(4S):S117–S314. PMID 38490803. Staging by eGFR (CKD-EPI 2021) and albuminuria, confirmation of albuminuria and of chronicity over three months, KFRE, a maximum-dose ACE inhibitor or ARB for albuminuria, an SGLT2 inhibitor for eGFR of at least 20 with a urine albumin-creatinine ratio of at least 200 mg/g with or without diabetes, potassium and creatinine 2 to 4 weeks after starting, acceptance of a creatinine rise of up to 30 percent, a statin for adults 50 or older with eGFR below 60 without routine repeat lipid testing, NSAID avoidance, and temporary withholding of these drugs during intercurrent illness. https://pubmed.ncbi.nlm.nih.gov/38490803/
2. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int* 2021;99(3S):S1–S87. PMID 33637192. Standardized office blood pressure and a systolic target below 120 mmHg when tolerated. https://pubmed.ncbi.nlm.nih.gov/33637192/
3. Whelton PK, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Hypertension* 2018;71(6):e13–e115. PMID 29133356. Target below 130/80 mmHg, out-of-office monitoring, sodium reduction, and activity. https://pubmed.ncbi.nlm.nih.gov/29133356/
4. CMID: Clinical Monitoring Intelligence Database (Aether Forge, 2026), chronic kidney disease, hypertension, and depression monographs. eGFR and urine albumin twice a year at G3a A2; a metabolic panel with each draw; potassium and creatinine 2 to 4 weeks after starting or titrating an ACE inhibitor, ARB, SGLT2 inhibitor, or MRA; calcium, phosphate, and PTH every 6 to 12 months at G3a; 25-hydroxyvitamin D at baseline; hemoglobin yearly in G3; one lipid panel; KFRE yearly; medication review and lifestyle counseling every visit; yearly vaccination review; blood pressure, weight, and cardiac auscultation every visit; a yearly fundoscopic examination and PHQ-9 in hypertension; no routine kidney imaging. https://patrickrutledge.github.io/topthirty/
5. U.S. Preventive Services Task Force: Depression and Suicide Risk in Adults (2023), Anxiety Disorders in Adults (2023), Breast Cancer (2024), Cervical Cancer (2018), Colorectal Cancer (2021), Osteoporosis (2025), Unhealthy Alcohol Use (2018), and the A and B recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
6. Centers for Disease Control and Prevention, Adult Immunization Schedule (PCV20, hepatitis B, influenza, recombinant zoster, COVID-19, and Tdap), and the Medicare Preventive Services reference (Aether Forge, 2026) for the preventive visit template. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html and https://patrickrutledge.github.io/preventative_services/

## Editorial resolutions

- **Index age.** The episode presents her at 54, in the period of ill health that the museum dates from late 1883 to her death, when her letters mention severe headache and nausea. The synthetic date of birth is December 10, 1971, so the whole-year shift is 141 years. The index home visit is January 12, 2026 (true frame January 12, 1885). The chronic-care visits follow on February 2, March 2, June 1, and September 28, 2026; the sick visit is April 20, 2026; the preventive visit is October 19, 2026 (true frame February 2, March 2, April 20, June 1, September 28, and October 19, 1885). She died in May 1886, so all fall within her lifetime. The visit type is `preventive_adult` because she is under 65. The visits are set at home, by video, or on two combined clinic trips, which does not conflict with her documented life at the Homestead.
- **Bright's disease and the kidney focus.** That her physician entered Bright's disease on her death certificate is documented (**D**). What that broad nineteenth-century label meant in her case is retrospective: the museum reports the conclusion that she died of heart failure caused by severe hypertension and notes the absence of documented signs of nephritis (**R**, possible). No blood pressure or kidney test from her lifetime exists. The stage G3a A2 chronic kidney disease and the hypertension are synthetic; both problems are placed both_with_link to these claims, and the record does not claim that she had chronic kidney disease. Heart failure is not added to the synthetic episode.
- **Eyes.** Her eye treatment in Boston and Cambridgeport in 1864 and 1865 is documented (**D**). The diagnosis is not recorded; iritis, exotropia, a psychiatric cause, and hysterical hyperaesthesia of the retina are retrospective proposals (**R**, disputed), so the past medical history entry is graded R and no eye diagnosis is coded. The modern episode adds only a yearly hypertensive eye examination and a negative eye review.
- **Withdrawal, anxiety, and mood.** Her withdrawal from social life is documented (**D**). Whether it was a choice or had a medical cause such as an anxiety condition is disputed (**R**, sensitive), and agoraphobia and social anxiety are not used as labels. The synthetic PHQ-9 (6, then 3) and GAD-7 (5, then 3) stay below the thresholds for a diagnosis, so no anxiety or depressive disorder is coded, no F code is used, and no safety assessment is required. The care plan respects her wish to stay at home and does not treat it as a disorder. The epilepsy hypothesis (**R**, disputed) is recorded only as a rejected interpretation.
- **Home-centered care.** The index visit, the sick visit, and the three-month review are home visits; the four-week and six-month reviews are video visits with vital signs from her own validated upper-arm cuff (checked against the clinic device at the first clinic trip), scale, thermometer, and pulse oximeter, the respiratory rate counted on video, and blood drawn at home by a mobile phlebotomy service; the height is the measured clinic value. Cardiac auscultation is recorded as deferred at the two video visits. The clinic is used only twice, each time for several tasks on one quiet early appointment. This echoes the documented difficulty her physician had in examining her (**D**) without attributing any statement to him.
- **Family and correspondents.** The family history is left empty, and the social history and advance care planning name no one, so that no health fact or statement is attributed to her relatives or correspondents. The deaths and illnesses of family members mentioned on the museum pages are not used; the October 1883 bereavement is recorded only as “a death in her family.” Quotations and the epithet her sister used are not used.
- **Not used.** The 1996 and 1999 *New England Quarterly* articles by Hirschhorn and Longsworth, Wand and Sewall's 1979 article on her eyes (no abstract available), Leyda's chronology, Gordon's biography, and the Poetry Foundation page (HTTP 403) were not read and are not cited. A 2008 article proposing post-traumatic stress reactions was found but not used. Her early consumptive symptoms are recorded without a tuberculosis diagnosis.
- **Sick and preventive visits.** The sick visit is a viral gastroenteritis with volume depletion and a prerenal creatinine rise (1.32 to 1.66 mg/dL, potassium 5.3 mmol/L) while she was taking losartan, dapagliflozin, and amlodipine, chosen to teach sick-day rules in chronic kidney disease. It does not echo any documented illness. The preventive visit adds negative PHQ-2, GAD-7, and AUDIT-C screens, cervical HPV testing (result pending), an ordered mammogram and home stool test (no results invented), HepB-CpG dose 2, influenza and zoster vaccines, and advance care planning that names no one.
- **Focused visits.** The four chronic-care follow-ups (three weeks, eight weeks, about five months, and about eight and a half months after intake) are documented as focused visits on the CMID chronic kidney disease and hypertension monographs with KDIGO 2024 and 2021. Synthetic findings introduced: an earlier eGFR of 58 and urine albumin-creatinine ratio of 190 mg/g fourteen months before intake (prose only, to establish chronicity); headaches and nausea that eased as blood pressure fell; her home cuff agreeing within 4 mmHg of the clinic device. One protocol deviation is recorded as `deferred`, with its outcome and corrective action, and no result was invented: the metabolic panel planned two to three days after the sick visit was not drawn (she declined the home draw, and the medicines were restarted without a recheck; no harm, creatinine back to 1.30 mg/dL six weeks later). Cardiac auscultation at the two video visits is recorded as deferred because it could not be done by video.
- **Consultation.** The nephrology referral and consultation (Samuel Adeyemi, MD, a fictional consultant, on the day of the first clinic trip) are **S**. The consultant confirms chronicity and A2 albuminuria on two samples, judges hypertensive kidney disease the probable cause with no need for biopsy or serology, and recommends what the record then shows: losartan raised to 100 mg, dapagliflozin 10 mg, potassium and creatinine in 2 to 4 weeks, a systolic target below 120 with amlodipine if needed, the urine albumin-creatinine ratio at about three months, vitamin D repletion with bone-mineral recheck at 6 to 12 months, NSAID avoidance, sick-day rules, and hepatitis B vaccination. Nephrology video review in about a year is planned beyond the end of the record.
- Dickinson died in 1886, so the recent-death review rule does not apply. Ordinary clinical, provenance, and safe-messaging reviews remain required.
